

# Sonora Quest Laboratories offers clarity in choosing from a broad portfolio of Maternal Serum Screening tests




Sonora Quest Laboratories supports your goals for Maternal Serum Screening (MSS)

- Maximize detection of fetal chromosomal abnormalities<sup>1</sup>
- Minimize false-positive test results<sup>1</sup>

...and offers a full range of test options

Weeks of Gestation



\* Hyperglycosylated human chorionic gonadotropin (h-hCG), formerly known as invasive trophoblast antigen (ITA)

† Chorionic villus sampling (CVS)

‡ Nuchal translucency (NT) is not a laboratory test and is not offered by Sonora Quest Laboratories. Measurements of NT performed locally by credentialed ultrasonographers are considered in conjunction with serum screens to calculate risk of fetal chromosomal abnormalities. NT measurement is typically performed from 10 4/7 - 13 6/7 weeks. For the above tests requiring an NT measurement, serum may be obtained prior to 10 4/7 weeks and the results calculated after NT is submitted.

Integrated Test Technology under license from Intema Ltd, UK.



# A Full Range of Maternal Serum Screening Tests

	First Trimester	First + Second Trimester			Second Trimester	
	1st Trimester Screen, h-hCG	Sequential Integrated Screen	Integrated Screen	Serum Integrated Screen	Penta Screen	Quad Screen
Down Syndrome Detection Rate	84% <sup>2</sup>	92% <sup>3</sup>	92% <sup>4</sup>	88% <sup>4</sup>	83% <sup>5</sup>	79% <sup>5</sup>
False-Positive Rate	5%	4%	3%	6%	5%	5%
CVS an Option?	Yes	Yes	No	No	No	No
NT Required?	Yes	Yes	Yes	No	No	No
Timing	9-13 <sup>6/7</sup> weeks	Part 1: 10-13 <sup>6/7</sup> weeks Part 2: 15-22 <sup>6/7</sup> weeks*	Part 1: 9-13 <sup>6/7</sup> weeks Part 2: 15-22 <sup>6/7</sup> weeks*	Part 1: 9-13 <sup>6/7</sup> weeks Part 2: 15-22 <sup>6/7</sup> weeks*	15-22 <sup>6/7</sup> weeks*	15-22 <sup>6/7</sup> weeks*
Serum Markers	PAPP-A h-hCG (Sonora Quest Laboratories exclusive through Quest Diagnostics)	Part 1: PAPP-A hCG Part 2: AFP hCG uE3 DIA	Part 1: PAPP-A Part 2: AFP hCG uE3 DIA	Part 1: PAPP-A Part 2: AFP hCG uE3 DIA	AFP hCG uE3 DIA h-hCG (Sonora Quest Laboratories exclusive through Quest Diagnostics)	AFP hCG uE3 DIA
Test Code	901714	Part 1: 903305 Part 2: 903317	Part 1: 903331 Part 2: 903323	Part 1: 903315 Part 2: 903316	902967	803139
CPT* Codes	82397; 84163	Part 1: 84702; 84163 Part 2: 82105; 84702 82677; 86336	Part 1: 84163 Part 2: 82105; 84702 82677; 86336	Part 1: 84163 Part 2: 82105; 84702 82677; 86336	82105; 84702; 82677; 86336; 82397	82105; 84702; 82677; 86336;

hCG = human chorionic gonadotropin; PAPP-A = pregnancy-associated plasma protein; AFP = alpha-fetoprotein; uE3 = unconjugated estriol; DIA = dimeric inhibin A

\* A second trimester specimen can be drawn as early as week 14, however Open Neural Tube Defect (ONTD) risk may not be reported for specimens drawn prior to 15 weeks.

#### References

- American College of Obstetricians and Gynecologists. Practice guidelines for fetal chromosomal abnormalities. *Practice Bulletin No. 77. Obstet Gynecol.* 2007;109:217-227.
- Palomaki GE, Knight GJ, Neveux LM, Pandian R, Haddow JE. Maternal serum invasive trophoblast antigen (ITA) and first trimester Down syndrome screening. *Clin Chem.* 2005;51(8):1499-1504.  
This study was partially funded by Quest Diagnostics. At the time of publication, co-author Raj Pandian was an employee of Quest Diagnostics.
- Palomaki GE, Neveux LM, Haddow JE, Wyatt P. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy. *Prenat Diagn.* 2007;27:808-813.  
This study was partially funded by Quest Diagnostics.
- Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. *BJOG* 2004;111:521-531.
- Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Pandian R. Maternal serum invasive trophoblast antigen (hyperglycosylated-hCG) as a screening marker for Down syndrome during the second trimester. *Clin Chem.* 2004;50(10):1804-1808.  
This study was partially funded by Quest Diagnostics. At the time of publication, co-author Raj Pandian was an employee of Quest Diagnostics.
- Wald, Rudnicka, Bestwick. Sequential and contingent prenatal screening for Down syndrome. *Prenatal Diagnosis* 2006;26:769-777.  
General Reference: Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both for down's syndrome. *N Engl J Med.* 2005;353(19):2001-2011.

\*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Sonora Quest Laboratories, the associated logo and marks are the registered trademarks of Sonora Quest Laboratories. All third party marks — '©' and '™' — are the property of their respective owners. © 2012 Sonora Quest Laboratories. All rights reserved.